Managing immune-related adverse events
Immune-related adverse events (irAEs) are side effects that can develop [...]
Avelumab plus axitinib combination shows promise
A clinical trial looking at the combination of avelumab plus [...]
Joint statement from the EAU and IKCC about the rejection of the ipilimumab plus nivolumab combination for kidney cancer by the EMA
The European Association of Urology (EAU) Renal Cell Cancer Guidelines [...]
Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer
A recent article in Annals of Oncology reports new patient-reported outcomes [...]
Cabozantinib approved as a first-line treatment option for advanced kidney cancer on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended [...]
Alternative sunitinib dosing schedule
A recent study carried out by a Japanese research team [...]
Highlights from video expert opinion on kidney cancer from ASCO 2018
The following video clips are useful highlights from video interviews [...]
Potential biomarkers may predict response to TKIs in metastatic kidney cancer
A recent study published in Clinical Cancer Research and conducted in [...]
IKCC statement on the negative opinion by the CHMP for the ipilimumab/nivolumab combination
The International Kidney Cancer Coalition (IKCC) have released the following [...]
Latest clinical trial results for the treatment of kidney cancer
These short videos explain the latest results from the following [...]
